drugset / Trial / NCT01822639

A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study

NCT01822639

Phase 1 Completed 15 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The study is designed to estimate the bioavailability of amlodipine and enalapril maleate fixed dose combination (FDC) relative to co-administration of amlodipine and enalapril maleate tablets. The rational for this study is to provide a more convenient dosing regimen for patients. This is an open-label, randomized, single dose, two-way crossover study, in which 16 healthy adult male and female subjects will be enrolled and dosed under fasting conditions. Each subject will participate in two treatment periods of 7 days each. There will be at least 14 days of wash out period between the two dosing periods and a follow-up period of up to 21 days after treatment period 2. The total duration of study will be approximately 35 days from the start of the first treatment.

Timeline

Start
2013-04-03
Primary completion
2013-05-24
Completion
2013-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Enalapril Other / unclassified 20 mg Oral
Subject GSK2944404 Unknown Oral

Indications